All News
Filter News
Found 375 articles
-
Electronic Skin Patches Market: Rise in Prevalence of Cardiovascular Diseases to Drive the Market
8/23/2022
Wilmington, Delaware, United States, Transparency Market Research Inc. – Electronic skin patches are considered to be ultimate wearable electronic devices
-
Biologics Contract Development Market Size, Share, Report 2022-2030
8/15/2022
The global biologics contract development market was estimated at USD 5.61 billion in 2021 and it is expected to surpass around USD 13.7 billion by 2030, poised to grow at a CAGR of 10.43% from 2022 to 2030
-
Y-mAbs Announces Second Quarter 2022 Financial Results and Recent Corporate Developments
8/8/2022
Y-mAbs Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported financial results for the second quarter of 2022.
-
Y-mAbs to Announce Second Quarter 2022 Financial and Operating Results on August 8, 2022
8/2/2022
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter that ended June 30, 2022, on Monday, August 8, 2022, after the close of the U.S. financial markets.
-
Tiziana Life Sciences Announces Presentation at Alzheimer’s Association International Conference® 2022 (AAIC®) Evaluating Intranasal anti-CD3 for the Potential Treatment of Alzheimer’s Disease
8/1/2022
Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel drug delivery approaches, today announced the presentation of a study entitled, “Treatment of Alzheimer’s disease by modulation of microglial neuroinflammation by nasal anti-CD3 mAb.”
-
Anti-PD-1 monoclonal antibody Puyouheng™ (HX-008, Pucotenlimab injection) Co-developed by LEPU BIOPHARMA and HANX BIOPHARMACEUTICALS was approved for marketing in China by NMPA
7/25/2022
PuyouhengTM (HX-008, pucotenlimab injection), was conditionally approved by the National Medical Products Administration (NMPA) for marketing in China to treat patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors, specifically.
-
ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177
7/21/2022
ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced the signing of a clinical supply agreement for its medical radioisotope no-carrier-added lutetium-177 with Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.
-
Downstream Processing Market Size to Worth Around US$ 24.2 BN by 2030
7/19/2022
The global downstream processing market size is predicted to be worth around US$ 24.2 billion by 2030 from valued at US$ 6.8 Bn in 2020, expanding growth at a rapid pace from 2020 to 2030.
-
Urinary Tract Infection Testing Market Size to Hit USD 765.9 Million by 2030
7/19/2022
The global urinary tract infection testing market size is expected to hit around USD 765.9 million by 2030 from valued at USD 554.1 million in 2021, growing at a CAGR of 3.66% during the forecast period 2022 to 2030.
-
Biopharmaceuticals Contract Manufacturing Market Size USD 27.5 Billion by 2030
7/14/2022
According to Latest Study, the global biopharmaceuticals contract manufacturing market was surpassed at USD 17.1 billion in 2021 and is expected to hit around USD 27.5 billion by 2030, growing at a CAGR of 5.42% from 2022 to 2030.
-
Y-mAbs’ Announces Clearance of IND for GD2-SADA
7/12/2022
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced initiation of its first clinical trial with a SADA construct.
-
Endoscopy Devices Market Size, CAGR, Trends | Forecast Report 2030
7/7/2022
According to Vision Research Reports, the global endoscopy devices market size is expected to be worth around US$ 72.9 billion by 2030.
-
Intravenous Infusion Pumps Market Size, Growth, Trends, Revenue, Report 2022-2030
7/7/2022
The global Intravenous Infusion Pumps market size is expected to be worth around US$ 10.4 billion by 2030, according to new report study.
-
PureTech Initiates Late-Stage Clinical Study of Wholly-Owned Candidate LYT-100 (Deupirfenidone) in IPF and Advances LYT-200 (Anti-Galectin-9 mAb)
6/30/2022
IPF study will evaluate efficacy of two doses of LYT-100, one with comparable exposure to FDA-approved dose of pirfenidone and one with higher exposure, vs. placebo, as well as relative tolerability and efficacy vs. pirfenidone.
-
The Medical Device Technologies Industry Is Poised To Experience A CAGR Of 3%, Anticipated To Close At A Valuation Of US$ 663 Billion: Fact.MR Study
6/24/2022
Fact.MR – A Market Research and Competitive Intelligence Provider: Demand for medical device technologies was valued at US$ 470.32 Billion in 2021, and is likely to flourish at a Y-o-Y expansion rate of 4.6% in 2022, reaching US$ 491.95 Billion.
-
Demand For Diagnostic Imaging Services Is Projected To Reach US$ 585 Million In 2022, Exhibiting A Y-O-Y Growth Rate Of 5.4%.
6/24/2022
Fact.MR – A Market Research and Competitive Intelligence Provider: Diagnostic imaging is an integral part of healthcare industries across many regions of the world.
-
Antibody Production Market to Experience Significant Growth During the Forecast Period 2031
6/21/2022
Wilmington, Delaware, United States: An antibody, otherwise called immunoglobulin, is a Y-molded protein created by the immune framework to shield the body from interlopers.
-
DermaSensor Inc. Announces Successful Completion of First Ever FDA Pivotal Studies for Skin Cancer Detection Device for Primary Care
6/20/2022
DermaSensor Inc., a health technology company designing non-invasive tools to better equip primary care physicians (PCPs) to detect skin cancer, has successfully met all primary endpoints for their two FDA pivotal studies.
-
Scilex Holding, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.
6/14/2022
Scilex Holding Company has entered into a license and commercialization agreement with RxOmeg Therapeutics LLC, a/k/a Romeg Therapeutics, LLC, for the exclusive right to market and distribute in the US Gloperba, an oral solution for adults suffering from gout.
-
Analysis from the Phase 3 N-MOmentum Study Demonstrates the Effectiveness of UPLIZNA® (inebilizumab-cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations
5/31/2022
Horizon Therapeutics plc (Nasdaq: HZNP) today announced data from the Phase 3 pivotal trial of UPLIZNA in NMOSD illustrating the treatment’s effectiveness among patients with different genetic make-ups.